Featured Abstracts
Review key findings and research highlights presented at major industry conferences and events.
Featured Content
ESTRO 2026
Preoperative radiotherapy in a single fraction for early stage breast cancer: the CRYSTAL phase I/II study update (AIRC IG-23118)
ESTRO 2026
Initial clinical experience of RayStation-based online adaptive RT using Radixact for endometrial cancer.
ESTRO 2026
One-year cumulative toxicity in 25 prostate cancer patients treated with single fraction (24 Gy) urethra-sparing radiosurgery (PRO-FAST NCT05936736 )
Featured Case Studies
Robotic Stereotactic Body Radiation Therapy For High-risk Prostate Cancer: The Georgetown University Experience
This retrospective study examines cancer control and health-related quality of life (HRQOL) outcomes in high-risk prostate cancer patients receiving robotic stereotactic body radiation therapy (SBRT) with Synchrony® real-time adaptive motion management.
Use of Motion Management to Model Unmanaged Motion: Dosimetric Consequences of Unmanaged Prostate Motion Assessed Using Real-time Radiotherapy Adaptation Data
This case report explores the dosimetric impact of unmanaged intrafraction prostate motion during radiotherapy by retrospectively analyzing real-time motion data collected using the Radixact® System with Synchrony®. The study models what would have happened if a patient had been treated without motion management, using deformation vector fields to simulate dose
Stereotactic Body Radiotherapy of a Lung Tumor with Large Respiratory Motion Using Real-time Adaptive Motion Management: A Case Report
Traditional internal target volume (ITV) methods for the treatment of a lung tumor on conventional linac would require a large planning target volume (PTV), risking high radiation exposure to the chest wall and lungs.
1651: Stereotactic Body Radiotherapy for Localized Kidney Cancer Compared with Standard Surgery Within a Young Academic Urologists Working Group Database
Michele Aquilano et al. | ESTRO | 2025
1021: RE-START: A National Registry Including Patients Undergoing Reirradiation After Previous RT for Prostate Cancer. A Study on Behalf of AIRO
Giulio Francolini et al. | ESTRO | 2025
2454: Robotic Stereotactic Body Radiotherapy for Malignant Liver Lesions: Local Control and Overall Survival – a Mono Institutional Study
Mariam Zurabashvili et al. | ESTRO | 2025
540: Liver SBRT in More Than 4 Fractions: Local Control and Recurrence Patterns
Alizée Renan et al. | ESTRO | 2025
3765: Re-irradiation Experience: Is it Underused in XXI Century?
Escarlata López et al. | ESTRO | 2025
3732: Use of Stereotactic Body Radiotherapy (SBRT) for Spine Metastases with Robotic Radiosurgery Unit CyberKnife in Patients with Oligometastatic Disease
Adrián Durango Méndez et al. | ESTRO | 2025
3389: Analysis of Local Control and Pain Relief of Rib Metastases Treated with Stereotactic Body Radiotherapy
Chiara Mattioli et al. | ESTRO | 2025
2718: Gastro-intestinal Toxicity: NTCP Models Based on CT-guided Online Adaptive SBRT for Abdominal Lymph Node Oligometastases
Lucy A van Werkhoven et al. | ESTRO | 2025
2332: Increased Iso-toxic Dose to the Target in Oligometastatic Abdominal Lymph Nodes Using CT-guided Online Adaptive SBRT
Lucy A. van Werkhoven et al. | ESTRO | 2025
1417: A Review of 130 CyberKnife Spinal Metastasis SABR Treatments at One Centre to Assess Risk of Spinal Cord Toxicity
Timothy Jackson et al. | ESTRO | 2025
1228: Preliminary Results of a CyberKnife SBRT for Extracranial Sites From a Tertiary Institute
Bhooshan Zade et al. | ESTRO | 2025
3605: Higher Disease-free Survival Observed for Complete Response After SBRT in Oligometastatic Gynecologic Tumors
Gaia Parma et al. | ESTRO | 2025
4246: Consecutive Radiosurgery for Multiple Brain Metastases with CyberKnife Robotic Radiosurgery Unit: Outcomes and Predictive Factors at a Hospital Center
Ignacio María Gómez Paloma et al. | ESTRO | 2025
4197: The Efficacy of CyberKnife® Stereotactic Radiation Therapy in Re-irradiation of Recurrent Glioblastoma.
Hanna Grzbiela et al. | ESTRO | 2025
4071: Hypofractionated Radiosurgery for Functioning and Non-functioning Pituitary Adenomas After Surgery: Our Working Experience with CyberKnife Unit
Julen Azcona Martin et al. | ESTRO | 2025
